Incyte (INCY) PT Lowered to $144 at BMO Capital

Go back to Incyte (INCY) PT Lowered to $144 at BMO Capital

Incyte (INCY) PT Lowered to $148 at Jefferies Following CRL

April 17, 2017 6:44 AM EDT

Jefferies lowered its price target on Incyte (NASDAQ: INCY) to $148.00 (from $165.00) while maintaining a Buy rating after the "surprising" CRL on Olumiant.

Analyst Brian Abrahams said while there could be many possibilities for the FDA issue their best guess is... More